medigraphic.com
ISSN 2992-779X (Digital)
ISSN 2007-6452 (Impreso)

2014, Número 1

<< Anterior Siguiente >>

Investigación en Discapacidad 2014; 3 (1)


Aspectos biológicos y clínicos para comprender mejor al osteosarcoma

Uribe-Rosales DD, Carranza-Arellano C, Ramos-Moreno R

Idioma: Español
Referencias bibliográficas: 39
Paginas: 33-40
Archivo PDF: 263.18 Kb.


RESUMEN

El osteosarcoma es una neoplasia de origen óseo-maligna que se presenta comúnmente en la segunda década de vida. En México, la información disponible en relación con esta patología se enfoca principalmente al área clínica, sin embargo, es fundamental conocer los aspectos moleculares involucrados en este proceso patológico. En esta revisión se muestra un panorama general de la información clínica y epidemiológica del osteosarcoma y se aborda, de manera más detallada, el conocimiento generado en relación con los mecanismos moleculares implicados en el desarrollo de esta enfermedad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. 1.Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007; 23: 2-6.

  2. 2.J-Klein M, P-Siegal G. Osteosarcoma anatomic and histologic variants. Am J Clin Pathol 2006; 125: 555-581.

  3. 3.Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: A review. Sarcoma. 2011; 2011. Article ID 959248, pages 15 doi: 10.1155/2011/959248.

  4. 4.Zhu L, McManus MM, Hughes DP. Understanding the biology of bone sarcoma from early initiating events through late events in metastasis and disease progression. Front Oncol. 2013; 17: 1-17.

  5. 5.Cuevas-Urióstegui ML, Villasis-Keever MA, Fajardo-Gutiérrez A. Epidemiología del cáncer en adolescentes. Salud Pública de México. 2003; 45: 115-123.

  6. 6.Baena-Ocampo LC, Ramírez-Pérez E, Linares-González LM, Delgado-Chávez R. Epidemiology of bone tumors in Mexico City: retrospective clinicopathologic study of 566 patients at a referral institution. Ann Diagn Pathol. 2009; 13: 16-21.

  7. 7.Nthumba PM. Osteosarcoma of the jaws: a review of literature and a case report on synchronous multicentric osteosarcomas. World J Surg Oncol. 2012; 10: 240.

  8. 8.Thariat J et al. Osteosarcomas of the mandible: Are they different from other tumor sites? Crit Rev Oncol Hematol. 2012; 82 (3): 280-95.

  9. 9.Neyssa M, Gebhardt M. Biology and therapeutic advances for pediatric osteosarcoma. The Oncologist. 2004; 9: 422-441.

  10. 10.Mirabello L, Troisi R, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer. 2009; 7: 1531-1543.

  11. 11.Savage A, Mirabello A. Epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011; 2011: 1-13.

  12. 12.Las-Heras F, Fernández GF, Capdeville FF. Osteosarcomas de la región de cabeza y cuello. Rev Chilena de Cirugía. 20011; 63 (5): 468-472.

  13. 13.McIntyre JF et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994; 12 (5): 925-930.

  14. 14.Franchi A, Arganini L, Baroni G et al. Expression of transforming growth factor beta isoforms in osteosarcoma variants: association of TGF beta 1 with high grade osteosarcomas. J Pathol. 1998; 185: 284-289.

  15. 15.Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 1998; 69: 21-27.

  16. 16.Nishida T, Nakanishi T, Asano M, Shimo T, Takigawa M. Effects of CTGF/Hcs24, a hypertrophic chondrocyte-specific gene product, on the proliferation and differentiation of osteoblastic cells in vitro. J Cell Physiol. 2000; 184: 197-206.

  17. 17.Nishida T, Emura K, Kubota S, Lyons KM, Takigawa M. CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. 2011; 26: 351-63.

  18. 18.Man T-K, Lu X-T, Jaeweon K. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer. 2004; 4: 45.

  19. 19.Suehara Y, Kubota D, Kikuta K. Discovery of Biomarkers for osteosarcoma by proteomics approaches. Sarcoma. 2012; 11-15.

  20. 20.Li FP et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988; 48: 5358-5362.

  21. 21.Malkin D et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 30: 1233-1238.

  22. 22.Franco-Hernández C, Martínez-Glez V, Rey JA. Biología molecular de los glioblastomas. Neurocirugía. 2007; 18: 373-382.

  23. 23.Pasello M et al. Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res. 2008; 68 (16): 6661-8.

  24. 24.Na KY, Kim YW, Park YK. Mitogen-activated protein kinase pathway in osteosarcoma. Pathology. 2012; 44 (6): 540-6.

  25. 25.Jenette K et al. Therapeutics, targets, and chemical biology expression and function of survivin in canine osteosarcoma. Cancer Res. 2012; 72: 249-259.

  26. 26.Wan et al. Oncogenic roles of astrocyte elevated gene-1 (AEG-1) in osteosarcoma progression and prognosis. Cancer Biol Ther. 2011; 12 (6): 539-548.

  27. 27.Lu XY et al. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol Cancer Res. 2008; 6: 937-46.

  28. 28.Zhang Z et al. Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines. BioMed Central Cancer. 2010; 10: 206.

  29. 29.Buecker P, Gebhardt M, Weber K. Osteosarcoma [Internet]. Liddy Shriver Sarcoma Initiative [Fecha de consulta: 30 octubre de 2013]. Disponible en: http://sarcomahelp.org/translate/es-osteosarcoma.html

  30. 30.Muscolo D et al. Actualización en osteosarcoma. Rev Asoc Argent Ortop Traumatol. 2009: 74 (1): 86-101.

  31. 31.Alderden R et al. The discovery and development of cisplatin. J Chem. 2006; 83: 728-724.

  32. 32.Hospital Infantil de México Federico Gómez [Página Web]. Protocolo de tratamiento de osteosarcoma en el Hospital Infantil de México Federico Gómez [Fecha de consulta: 30 de octubre de 2013]. Disponible en: http://www.himfg.edu.mx/descargas/documentos/planeacion/guiasclinicasHIM/Osteosarcoma.pdf

  33. 33.Yancey A et al. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012; 59: 144-148.

  34. 34.Pérez C et al. Cardiotoxicidad tardía inducida por antraciclinas. Med Clin (Barc). 2009; 133 (8): 311-313.

  35. 35.Sociedad Española de Farmacéuticos de Hospitales. Medicamentos citostáticos. 4a ed. Madrid: Raíz; 2005.

  36. 36.Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011; 47 (16): 2431-45.

  37. 37.Akiyama T, R-Dass C, M-Choong P. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone resorbing activity, and apoptosis pathway. Mol Cancer Ther. 2008; 7: 3461-3469.

  38. 38.Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009; 28: 247-263.

  39. 39.Akiyama T, R-Dass C, M-Choong P. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone resorbing activity, and apoptosis pathway. Mol Cancer Ther. 2008; 7: 3461-3469.




2020     |     www.medigraphic.com